Answers are grounded in this paper and cite their sources.
This cohort study assesses patients’ use of brand-name and generic lenalidomide following the first generic market entrant in March 2022.
No takes yet. Share an insight, caveat, or question.
Jazowski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: